ArticleJournal for immunotherapy of cancer2022

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.

Kristin G Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.